Navigation Links
Promising advances in islet cell transplants for diabetes
Date:6/9/2008

University of Illinois at Chicago researchers have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells.

The study results are published in the June issue of the American Journal of Transplantation.

UIC is one of only a few centers worldwide able to achieve reproducible and consistent insulin independence in severe type 1 diabetes patients.

In the UIC study, 10 patients with diabetes received between one and three islet cell transplants and were followed for 15 months.

Four received the Edmonton protocol, developed at the University of Alberta, which uses a combination of two immunosuppressants and a monoclonal antibody drug, daclizumab.

Six patients received the UIC protocol -- a combination of etanercept (an anti-inflammatory drug developed to treat rheumatoid arthritis) and exenatide (a drug approved for use in type 2 diabetes to improve glucose control) -- and the Edmonton regimen.

The new procedure allowed patients to get off insulin after a single transplant versus the two to four transplants that were needed using the older protocol, said Dr. Jos Oberholzer, director of cell and pancreas transplantation at UIC and lead author of the study.

All patients in the study achieved insulin independence, but those who received the UIC protocol required fewer than half the number of islets as those who were treated under the Edmonton protocol.

The four patients who received the Edmonton protocol needed either two or three sequential islet cell transplants to achieve insulin-independence.

The six patients who were treated using the UIC protocol initially achieved insulin-independence after only one islet transplant. Two of these patients required a second islet cell transplant, and one resumed insulin five months after the second transplant due to other complications.

Progress in islet cell transplantation has been limited by the shortage of donor organs, said Oberholzer, who is associate professor of surgery, bioengineering and endocrinology at UIC.

"This study is extremely promising and shows that we can achieve success with fewer islet cells, freeing patients from the need to check their insulin, even after 20 or 30 years of suffering from diabetes," he said.

UIC is one of seven federally funded National Institutes of Health Islet Cell Resource Centers across the country that provides researchers with human pancreatic islet cells for transplantation into diabetic patients and for basic science research on diabetes.

"We have proven that if you have the right team and the right environment you can achieve islet cell transplantation success in a very short time," said Oberholzer, who has led UIC's program since 2003.

Building on results from Oberholzer's study, UIC is participating in the Clinical Islet Transplant Consortium, funded by the NIH to identify the most effective combination of anti-rejection drugs to maximize islet engraftment while reducing toxic side-effects.


'/>"/>

Contact: Sherri McGinnis Gonzalez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
(Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
Breaking Medicine Technology: